4.07
-0.01(-0.25%)
Currency In USD
| Previous Close | 4.08 |
| Open | 4.13 |
| Day High | 4.13 |
| Day Low | 3.94 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.11 |
| Volume | 2.7M |
| Average Volume | 4.32M |
| Market Cap | 725.26M |
| PE | -2.61 |
| EPS | -1.56 |
| Moving Average 50 Days | 3.85 |
| Moving Average 200 Days | 2.63 |
| Change | -0.01 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $264.8 as of September 13, 2025 at a share price of $4.07. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 2 years ago, it would be worth $322.5 as of September 13, 2025 at a share price of $4.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Aug 01, 2025 8:01 PM GMT
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwrit
Prime Medicine Announces Pricing of Public Offering
GlobeNewswire Inc.
Jul 31, 2025 1:33 AM GMT
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritt
Prime Medicine Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Jul 30, 2025 8:01 PM GMT
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an und